Tanım

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 sırasında milyar 2021-2027, yıllık bileşik büyüme oranında büyüyor (CAGR) ile ilgili 8.6% tahmin dönemi boyunca, veri ve analiz şirketi StratejiHelix'e göre. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2017-2020 ve tahmin 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, teknoloji, age, analysis target, ve bölge. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. Teknolojiye göre, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, ve diğerleri. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
Teknoloji: polymerase chain reaction (PCR), next-generation sequencing, microarrays, ve diğerleri
Age: children, and adult
Bölge: Kuzey Amerika, Asya Pasifik, Avrupa, and Rest of the World (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
Düşünülen Yıllar: bu rapor dönemi kapsamaktadır 2017 ile 2027

Paydaşlar için Temel Faydalar

Get a comprehensive picture of the global rare disease diagnostics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Büyüme sektörlerini ve yatırım eğilimlerini belirleyin
Understand what the future of the global rare disease diagnostics market looks like
Rekabet ortamını ve fırsat penceresini belirleyin

İçindekiler

1. Pazar Tanımı
2. Araştırma Metodolojisi
3. Piyasa verileri & Görünüm
3.1 Market değeri
3.2 Piyasa Değeri Tahmini
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 Diğerleri
6. Rare Disease Diagnostics Market by Age
6.1 Children
6.2 Adult
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 Kuzey Amerika
8.2 Asya Pasifik
8.3 Avrupa
8.4 Rest Of The World (Row)
9. Şirket profilleri
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, A.Ş..
9.10 Quest Diagnostics Incorporated
10. Ek
10.1 StratejiHelix Hakkında
10.2 Sorumluluk reddi beyanı